PTCT Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of 20.1%. PTC Therapeutics, Inc.'s return on equity of -- beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.

PTC Therapeutics, Inc. has a consensus price target of $88.50, signalling upside risk potential of 18.51%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 46.21%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than PTC Therapeutics, Inc..

PTC Therapeutics, Inc. has a beta of 0.484, which suggesting that the stock is 51.641% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

PTC Therapeutics, Inc. quarterly revenues are $211M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. PTC Therapeutics, Inc.'s net income of $15.9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 8.73x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,364.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.45x versus 13.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Keros Therapeutics, Inc. has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of -51.05%. PTC Therapeutics, Inc.'s return on equity of -- beat Keros Therapeutics, Inc.'s return on equity of 9.94%.

PTC Therapeutics, Inc. has a consensus price target of $88.50, signalling upside risk potential of 18.51%. On the other hand Keros Therapeutics, Inc. has an analysts' consensus of $23.38 which suggests that it could grow by 33.04%. Given that Keros Therapeutics, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Keros Therapeutics, Inc. is more attractive than PTC Therapeutics, Inc..

PTC Therapeutics, Inc. has a beta of 0.484, which suggesting that the stock is 51.641% less volatile than S&P 500. In comparison Keros Therapeutics, Inc. has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.332%.

PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Keros Therapeutics, Inc. pays out -- of its earnings as a dividend.

PTC Therapeutics, Inc. quarterly revenues are $211M, which are larger than Keros Therapeutics, Inc. quarterly revenues of $14.3M. PTC Therapeutics, Inc.'s net income of $15.9M is higher than Keros Therapeutics, Inc.'s net income of -$7.3M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 8.73x while Keros Therapeutics, Inc.'s PE ratio is 11.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.45x versus 2.89x for Keros Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of -45.06%. PTC Therapeutics, Inc.'s return on equity of -- beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

PTC Therapeutics, Inc. has a consensus price target of $88.50, signalling upside risk potential of 18.51%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 15.86%. Given that PTC Therapeutics, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe PTC Therapeutics, Inc. is more attractive than Sarepta Therapeutics, Inc..

PTC Therapeutics, Inc. has a beta of 0.484, which suggesting that the stock is 51.641% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.

PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

PTC Therapeutics, Inc. quarterly revenues are $211M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. PTC Therapeutics, Inc.'s net income of $15.9M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 8.73x while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.45x versus 0.79x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spyre Therapeutics, Inc. has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of --. PTC Therapeutics, Inc.'s return on equity of -- beat Spyre Therapeutics, Inc.'s return on equity of -28.51%.

PTC Therapeutics, Inc. has a consensus price target of $88.50, signalling upside risk potential of 18.51%. On the other hand Spyre Therapeutics, Inc. has an analysts' consensus of $56.43 which suggests that it could grow by 60.67%. Given that Spyre Therapeutics, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than PTC Therapeutics, Inc..

PTC Therapeutics, Inc. has a beta of 0.484, which suggesting that the stock is 51.641% less volatile than S&P 500. In comparison Spyre Therapeutics, Inc. has a beta of 3.152, suggesting its more volatile than the S&P 500 by 215.196%.

PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spyre Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Spyre Therapeutics, Inc. pays out -- of its earnings as a dividend.

PTC Therapeutics, Inc. quarterly revenues are $211M, which are larger than Spyre Therapeutics, Inc. quarterly revenues of --. PTC Therapeutics, Inc.'s net income of $15.9M is higher than Spyre Therapeutics, Inc.'s net income of -$11.2M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 8.73x while Spyre Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.45x versus 701.12x for Spyre Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.